Kisqali Prices, Coupons, Copay Cards & Patient Assistance
Kisqali (ribociclib) is a member of the CDK 4/6 inhibitors drug class and is commonly used for Breast Cancer, and Breast Cancer - Metastatic.
Kisqali is available as a brand name drug only, a generic version is not yet available. View generic Kisqali availability for more details.
Kisqali prices
Oral Tablet
200 mg (200 mg daily-dose) Kisqali oral tablet from $8,165.91 for 21 tablets
| Quantity | Per unit | Price |
|---|---|---|
| 21 | $388.85 | $8,165.91 |
Important: When there is a range of pricing, consumers should normally expect to pay the lower price. However, due to stock shortages and other unknown variables we cannot provide any guarantee.
200 mg (400 mg daily-dose) Kisqali oral tablet from $16,321.87 for 42 tablets
| Quantity | Per unit | Price |
|---|---|---|
| 42 (3 x 14 each) | $388.62 | $16,321.87 |
Important: When there is a range of pricing, consumers should normally expect to pay the lower price. However, due to stock shortages and other unknown variables we cannot provide any guarantee.
200 mg (600 mg daily-dose) Kisqali oral tablet from $20,399.85 for 63 tablets
| Quantity | Per unit | Price |
|---|---|---|
| 63 (3 x 21 each) | $323.81 | $20,399.85 |
Important: When there is a range of pricing, consumers should normally expect to pay the lower price. However, due to stock shortages and other unknown variables we cannot provide any guarantee.
Get your FREE Drugs.com Discount Card
Save up to 80% off the cost of prescription drugs and OTC medicines valid at over 65,000 pharmacies.
This is a drug discount program, not an insurance plan.
Kisqali Coupons, Copay Cards and Rebates
Kisqali offers may take the form of printable coupons, rebates, savings or copay cards, trial offers, or free samples. Certain offers may be printable from a website while others may require registration, completing a questionnaire, or obtaining a sample from a medical professional.
Kisqali $0 Co-Pay Plus Offer
Eligible commercially insured patients may pay $0 per prescription with a maximum savings of $15,000 per calendar year
- Applies to:
- Kisqali
- Number of uses:
- per prescription per calendar year
Form more information phone: 866-433-8000 or Visit website
Kisqali Free Trial Offer
Eligible patients may receive a 1-treatment cycle supply for free; for additional information contact the program at 800-282-7630.
- Applies to:
- Kisqali
- Number of uses:
- One-time offer
Form more information phone: 866-433-8000 or Visit website
Kisqali 5-Treatment Cycle Access
Eligible commercially insured patients who are still waiting for coverage may be eligible for an additional supply of Kisqali that could continue for up to 5 treatment cycles.
- Applies to:
- Kisqali
- Number of uses:
- Temporary Assistance
Form more information phone: 866-433-8000 or Visit website
Patient Assistance & Copay Programs for Kisqali
Patient assistance programs (PAPs) are typically sponsored by pharmaceutical companies and offer cost-free or discounted medicines, as well as copay programs, to individuals with low income or those who are uninsured/under-insured and meet specific criteria. Eligibility requirements for each program may vary.
Provider: Novartis Patient Assistance Foundation, Inc. (NPAF)
Eligibility requirements:- Contact program for details.
- Based on FPL
- Not specified
- Must be residing in the US or US territory
- Fabhalta: To start the application process apply to support.Fabhalta.com or (833) 993-2242. Kesimpta: To start the application process apply to Alongside™ Kesimpta at www.Kesimpta.com or (855) 537-4678. Kisqali: To start the application process apply to support.Kisqali.com or (866) 433-8000. Leqvio: To start the application process apply to Leqvio Service Center at www.Leqvio.com or (833) 537-8462. Lutathera: To start the application process call (844) 638-7222. Pluvicto: To start the application process call (844) 638-7222. Scemblix: To start the application process apply to support.Scemblix.com or (866) 433-8000. All medication will be shipped directly to the patient, unless otherwise noted. Please contact the program for a complete product listing. www.pap.novartis.com
- Kisqali (ribociclib) Tablet
More information please phone: 800-277-2254 Visit website
Provider: HealthWell Foundation Copay Program
Eligibility requirements:- May have insurance
- Varies
- FDA Approved Diagnosis - See Program Website for Details
- The patient must also be residing in the US.
- This program provides financial assistance to eligible individuals to cover coinsurance, copayments, healthcare premiums and deductibles for certain treatments. Also, for those who are eligible for health insurance, but cannot afford the insurance premium, the foundation may be able to help by paying some or all of the medical portion of insurance premiums. The patient is being treated for a specific disease for which funding is available and has insurance that covers the treatment for this disease. Call for most recent medications as the list is subject to change.
- Kisqali (ribociclib) Tablet
- Kisqali Femara (ribociclib and letrozole) Tablet/Tablet co-packaged
More information please phone: 800-675-8416 Visit website
Provider: Patient Access Network Foundation (PAN)
Eligibility requirements:- *See Additional Information section below
- Between 400-500% of FPL
- FDA Approved Diagnosis - See Program Website for Details
- Must reside and receive treatment in US
- *Patients must have health insurance and their insurance must cover the qualifying medication for which they seek assistance. Call for most recent medications as the list is subject to change and the medication for which you are seeking assistance must treat the disease directly. Note: All new enrollment is now done electronically or over the phone. Contact program for details.
- Kisqali (ribociclib) Tablet
- Kisqali Femara (ribociclib-letrozole) Tablet/Tablet co-packaged
More information please phone: 866-316-7263 Visit website
Disclaimer: Medication pricing is sourced from a variety of providers. Pricing may vary significantly due to several factors including brand or generic status, insurance coverage, pharmacy choice, location, and manufacturer pricing policies. Prices are subject to change. For the most accurate and up-to-date information, always consult directly with your pharmacy or healthcare provider.
See also:
Trodelvy
Trodelvy (sacituzumab govitecan) is a targeted therapy used to treat breast cancer (triple-negative ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Verzenio
Verzenio is used to treat early and advanced-stage hormone receptor-positive, HER2-negative breast ...
Keytruda
Keytruda is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma ...
Arimidex
Arimidex is used to treat breast cancer in postmenopausal women. Learn about side effects ...
Femara
Femara lowers estrogen levels and is used to treat breast cancer in postmenopausal women. Learn ...
Ibrance
Ibrance is used to treat HR-positive, HER2-negative breast cancer in postmenopausal women or men ...
Xeloda
Xeloda is used to treat breast and colorectal cancers. Learn about side effects, interactions and ...
Herceptin
Herceptin is used to treat patients with metastatic breast cancer. Learn about side effects ...
More about Kisqali (ribociclib)
- Check interactions
- Compare alternatives
- Reviews (34)
- Imprints, shape & color data
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: CDK 4/6 inhibitors
- Breastfeeding
- En español